Colorectal Cancer: From Genetic Landscape to Targeted Therapy.

Tytuł:: Colorectal Cancer: From Genetic Landscape to Targeted Therapy.
Autorzy:: El Bali M; Biomedical Genomics and Oncogenetics Research Laboratory, Faculty of Sciences and Techniques of Tangier, Abdelmalek Essaâdi University, Tetouan, Morocco.
Bakkach J; Biomedical Genomics and Oncogenetics Research Laboratory, Faculty of Sciences and Techniques of Tangier, Abdelmalek Essaâdi University, Tetouan, Morocco.
Bennani Mechita M; Biomedical Genomics and Oncogenetics Research Laboratory, Faculty of Sciences and Techniques of Tangier, Abdelmalek Essaâdi University, Tetouan, Morocco.
Źródło:: Journal of oncology [J Oncol] 2021 Jul 06; Vol. 2021, pp. 9918116. Date of Electronic Publication: 2021 Jul 06 (Print Publication: 2021).
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Original Publication: Cairo : Hindawi Publishing Corporation
References:: Cell. 1998 Oct 2;95(1):29-39. (PMID: 9778245)
Sci Transl Med. 2011 Sep 7;3(99):99ra86. (PMID: 21900593)
Cancer Biol Ther. 2013 Dec;14(12):1143-6. (PMID: 24025416)
Int J Cancer. 2012 Aug 15;131(4):980-6. (PMID: 21960311)
Cancer Res. 1998 Nov 15;58(22):5248-57. (PMID: 9823339)
Clin Cancer Res. 2011 May 15;17(10):3146-56. (PMID: 21447729)
BMC Med Genomics. 2012 Dec 31;5:66. (PMID: 23272949)
J Clin Oncol. 2010 Nov 1;28(31):4706-13. (PMID: 20921462)
Transl Oncol. 2018 Oct;11(5):1188-1201. (PMID: 30071442)
Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):11-27. (PMID: 15000146)
BMC Cancer. 2019 Nov 27;19(1):1155. (PMID: 31775679)
Cancer Discov. 2011 Nov;1(6):508-23. (PMID: 22586653)
PLoS Med. 2013;10(5):e1001453. (PMID: 23700391)
Sci Data. 2017 Sep 05;4:170120. (PMID: 28872635)
Nat Med. 2015 Nov;21(11):1350-6. (PMID: 26457759)
Cancer Res. 1984 Mar;44(3):1002-7. (PMID: 6318979)
Oncogene. 2000 Jan 27;19(4):546-55. (PMID: 10698524)
Cancer Res. 1998 Mar 15;58(6):1130-4. (PMID: 9515795)
World J Gastrointest Oncol. 2010 Mar 15;2(3):151-8. (PMID: 21160823)
Lancet Oncol. 2010 Aug;11(8):753-62. (PMID: 20619739)
N Engl J Med. 2008 Oct 23;359(17):1757-65. (PMID: 18946061)
Cancer Biol Ther. 2020 Oct 2;21(10):891-898. (PMID: 33026965)
N Engl J Med. 2004 Jun 3;350(23):2335-42. (PMID: 15175435)
Lancet. 2019 Oct 19;394(10207):1467-1480. (PMID: 31631858)
Virchows Arch. 2016 Aug;469(2):125-34. (PMID: 27325016)
J Clin Oncol. 2007 Apr 20;25(12):1539-44. (PMID: 17442997)
Nat Rev Cancer. 2009 Aug;9(8):550-62. (PMID: 19629070)
Cancer Res. 2009 Mar 1;69(5):1851-7. (PMID: 19223544)
Oncotarget. 2018 Apr 10;9(27):18698-18711. (PMID: 29721154)
Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6. (PMID: 10411935)
Curr Colorectal Cancer Rep. 2016;12:141-150. (PMID: 27340376)
J Clin Oncol. 2009 Jul 1;27(19):3117-25. (PMID: 19451425)
PLoS One. 2013 Dec 18;8(12):e84604. (PMID: 24367680)
Oncology. 2010;78(5-6):376-81. (PMID: 20798560)
Ann Oncol. 2014 Oct;25(10):2008-2014. (PMID: 25009008)
Nature. 2012 Jun 28;486(7404):537-40. (PMID: 22722843)
J Clin Oncol. 2008 May 10;26(14):2311-9. (PMID: 18390971)
Ann Oncol. 2018 Nov 1;29(11):2240-2246. (PMID: 30247524)
Clin Cancer Res. 2020 Dec 15;26(24):6559-6567. (PMID: 32943459)
Onco Targets Ther. 2016 Mar 31;9:1899-920. (PMID: 27099521)
J Clin Oncol. 2019 Aug 1;37(22):1876-1885. (PMID: 31042420)
J Cancer. 2016 Mar 20;7(6):633-49. (PMID: 27076844)
Cancers (Basel). 2019 Oct 15;11(10):. (PMID: 31618962)
World J Gastroenterol. 2016 Jul 28;22(28):6345-61. (PMID: 27605871)
Ann Oncol. 2014 Jul;25(7):1346-1355. (PMID: 24718886)
J Clin Oncol. 2010 Jul 1;28(19):3191-8. (PMID: 20516443)
Gastroenterology. 2010 Jun;138(6):2059-72. (PMID: 20420946)
Int J Cancer. 2019 Feb 1;144(3):569-581. (PMID: 30252132)
Br J Cancer. 2013 Feb 19;108(3):668-75. (PMID: 23348520)
Gut Liver. 2017 Jan 15;11(1):38-46. (PMID: 27885175)
Lancet. 2013 Jan 26;381(9863):303-12. (PMID: 23177514)
N Engl J Med. 2008 Mar 13;358(11):1160-74. (PMID: 18337605)
J Pathol. 2019 Apr;247(5):574-588. (PMID: 30584801)
N Engl J Med. 2008 Mar 13;358(11):1148-59. (PMID: 18337604)
J Clin Oncol. 2009 Dec 10;27(35):5924-30. (PMID: 19884556)
Biochim Biophys Acta. 2015 Jan;1855(1):104-21. (PMID: 25450577)
Drugs. 2019 Jan;79(1):63-74. (PMID: 30617958)
Breast Cancer Res Treat. 2015 Jun;151(3):481-9. (PMID: 25947646)
Nat Med. 2012 Jan 22;18(2):221-3. (PMID: 22270724)
Int J Mol Sci. 2017 Sep 14;18(9):. (PMID: 28906427)
CA Cancer J Clin. 2019 Jan;69(1):7-34. (PMID: 30620402)
Cancer Discov. 2014 Nov;4(11):1269-80. (PMID: 25293556)
Hematol Oncol Clin North Am. 2010 Oct;24(5):837-59. (PMID: 20816577)
J Clin Oncol. 2009 Jun 1;27(16):2622-9. (PMID: 19398573)
Ann Oncol. 2019 Nov 1;30(11):1796-1803. (PMID: 31868905)
Cancer Biol Ther. 2014 May;15(5):623-32. (PMID: 24556630)
Clin Cancer Res. 2011 Feb 1;17(3):472-82. (PMID: 21098338)
Oncol Rep. 2006 Dec;16(6):1245-52. (PMID: 17089045)
Ann Gastroenterol Surg. 2020 Jul 21;4(5):528-539. (PMID: 33005848)
Int J Cancer. 2014 Feb 1;134(3):552-62. (PMID: 23852808)
Int J Clin Oncol. 2019 Sep;24(9):999-1011. (PMID: 31273487)
BMC Cancer. 2008 Aug 13;8:234. (PMID: 18700047)
Prz Gastroenterol. 2019;14(2):89-103. (PMID: 31616522)
J Gastroenterol Hepatol. 2012 Sep;27(9):1423-31. (PMID: 22694276)
N Engl J Med. 2019 Oct 24;381(17):1632-1643. (PMID: 31566309)
JAMA. 2018 Jun 26;319(24):2486-2496. (PMID: 29946728)
Cell. 1990 Jun 1;61(5):759-67. (PMID: 2188735)
Cancer Cell. 2019 Feb 11;35(2):315-328.e6. (PMID: 30753828)
Nature. 2002 Jun 27;417(6892):949-54. (PMID: 12068308)
Cancer Discov. 2015 Jan;5(1):43-51. (PMID: 25358689)
Signal Transduct Target Ther. 2020 Mar 20;5(1):22. (PMID: 32296018)
J Clin Oncol. 1992 Jun;10(6):896-903. (PMID: 1534121)
Mol Diagn Ther. 2015 Dec;19(6):397-408. (PMID: 26341080)
Int J Mol Sci. 2018 Jun 16;19(6):. (PMID: 29914167)
Cancer Cell. 2014 Mar 17;25(3):282-303. (PMID: 24651011)
Mol Oncol. 2014 Sep 12;8(6):1084-94. (PMID: 24913799)
Carcinogenesis. 2003 Apr;24(4):703-10. (PMID: 12727799)
Gut. 2007 Jan;56(1):140-8. (PMID: 16840508)
Nat Rev Clin Oncol. 2010 Apr;7(4):197-208. (PMID: 20177404)
Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):713-732. (PMID: 31455888)
Chin J Cancer. 2017 Dec 22;36(1):97. (PMID: 29273089)
Br J Surg. 2002 Jul;89(7):845-60. (PMID: 12081733)
J Clin Oncol. 2009 Oct 20;27(30):5068-74. (PMID: 19738126)
J Clin Oncol. 2007 May 1;25(13):1658-64. (PMID: 17470858)
J Cancer Res Clin Oncol. 2013 Mar;139(3):367-78. (PMID: 23099994)
Cancer J. 2011 Nov-Dec;17(6):405-15. (PMID: 22157284)
World J Gastroenterol. 2007 Jul 28;13(28):3784-91. (PMID: 17657831)
J Pathol. 2013 Sep;231(1):63-76. (PMID: 23836465)
J Clin Oncol. 2009 Apr 20;27(12):2091-6. (PMID: 19188670)
Nat Med. 2013 May;19(5):614-8. (PMID: 23584090)
Int J Cancer. 2011 Jul 1;129(1):245-55. (PMID: 21170960)
Cancers (Basel). 2019 Nov 09;11(11):. (PMID: 31717544)
J Clin Oncol. 2007 Aug 1;25(22):3230-7. (PMID: 17664471)
J Clin Oncol. 2012 Oct 10;30(29):3596-603. (PMID: 22965965)
Lancet Oncol. 2012 Apr;13(4):e178-85. (PMID: 22469128)
Gastroenterology. 2010 Jun;138(6):2073-2087.e3. (PMID: 20420947)
J Clin Oncol. 2012 Oct 1;30(28):3499-506. (PMID: 22949147)
Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9719-23. (PMID: 11481457)
Mol Oncol. 2018 Jan;12(1):3-20. (PMID: 29124875)
J Mol Med (Berl). 2014 Jul;92(7):677-9. (PMID: 24890523)
N Engl J Med. 2009 Apr 2;360(14):1408-17. (PMID: 19339720)
Langenbecks Arch Surg. 2015 Feb;400(2):129-43. (PMID: 25701352)
Nat Med. 2013 May;19(5):619-25. (PMID: 23584089)
Fam Cancer. 2004;3(2):101-7. (PMID: 15340260)
Biochimie. 2019 Feb;157:64-71. (PMID: 30414835)
Ann Oncol. 2016 Dec;27(12):2216-2224. (PMID: 27733377)
Nat Rev Dis Primers. 2015 Nov 05;1:15065. (PMID: 27189416)
Cancer Chemother Pharmacol. 2012 Jun;69(6):1647-55. (PMID: 22610356)
Nature. 2012 Jun 28;486(7404):532-6. (PMID: 22722830)
Br J Cancer. 2013 Apr 2;108(6):1316-23. (PMID: 23449351)
JAMA Oncol. 2016 Sep 1;2(9):1162-9. (PMID: 27270348)
Gastroenterol Res Pract. 2015;2015:753903. (PMID: 25983749)
Nature. 1992 Sep 17;359(6392):235-7. (PMID: 1528264)
Neoplasia. 2005 Jun;7(6):545-55. (PMID: 16036105)
Ann Oncol. 2012 Jun;23(6):1518-25. (PMID: 22039088)
Nature. 2012 Jul 18;487(7407):330-7. (PMID: 22810696)
Clin Cancer Res. 2013 Dec 15;19(24):6751-65. (PMID: 24122793)
Eur J Cancer. 2012 Jul;48(10):1466-75. (PMID: 22446022)
Nat Rev Mol Cell Biol. 2006 May;7(5):335-46. (PMID: 16612326)
J Adenocarcinoma. 2016;1(2):. (PMID: 30370422)
J Clin Oncol. 2003 Jan 1;21(1):60-5. (PMID: 12506171)
Ecancermedicalscience. 2020 Jul 13;14:1069. (PMID: 32728385)
World J Gastrointest Surg. 2015 Mar 27;7(3):25-32. (PMID: 25848489)
Crit Rev Oncol Hematol. 2017 Jan;109:9-19. (PMID: 28010901)
N Engl J Med. 2004 Jul 22;351(4):337-45. (PMID: 15269313)
JAMA Oncol. 2016 May 1;2(5):633-642. (PMID: 26867820)
Lancet Oncol. 2013 Jan;14(1):29-37. (PMID: 23168366)
Clin Cancer Res. 2018 Feb 15;24(4):794-806. (PMID: 29242316)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Ann Oncol. 2019 Apr 1;30(4):520-527. (PMID: 30796810)
Br J Cancer. 2007 Oct 22;97(8):1139-45. (PMID: 17940504)
Int J Mol Sci. 2013 Aug 07;14(8):16365-85. (PMID: 23965959)
Clin Cancer Res. 2006 Sep 15;12(18):5268-72. (PMID: 17000658)
J Clin Oncol. 2009 Feb 10;27(5):663-71. (PMID: 19114683)
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):191-5. (PMID: 14734469)
Anticancer Drugs. 2007 Jan;18(1):7-15. (PMID: 17159497)
Nat Genet. 2006 Jul;38(7):787-93. (PMID: 16804544)
J Clin Oncol. 2008 Feb 1;26(4):689-90. (PMID: 18235136)
J Clin Oncol. 2008 Apr 20;26(12):2013-9. (PMID: 18421054)
Diagn Pathol. 2016 Jul 08;11(1):61. (PMID: 27392434)
Clin Colorectal Cancer. 2013 Mar;12(1):28-36. (PMID: 23083634)
Br J Cancer. 2009 Aug 18;101(4):715-21. (PMID: 19603018)
Br J Cancer. 2015 Jun 9;112(12):1888-94. (PMID: 25989278)
N Engl J Med. 2013 Sep 12;369(11):1023-34. (PMID: 24024839)
Biologics. 2014;8:13-25. (PMID: 24368879)
Oncotarget. 2017 Jan 17;8(3):3980-4000. (PMID: 28002810)
Nat Rev Clin Oncol. 2010 Mar;7(3):153-62. (PMID: 20142816)
J Dig Dis. 2013 Aug;14(8):409-16. (PMID: 23615046)
Cancer Discov. 2013 Jun;3(6):658-73. (PMID: 23729478)
Entry Date(s):: Date Created: 20210730 Latest Revision: 20210731
Update Code:: 20240105
PubMed Central ID:: PMC8277501
DOI:: 10.1155/2021/9918116
PMID:: 34326875
: Czasopismo naukowe

Pełny tekst

Colorectal cancer (CRC) is the third most common cancer type and the second cause of death worldwide. The advancement in understanding molecular pathways involved in CRC has led to new classifications based on the molecular characteristics of each tumor and also improved CRC management through the integration of targeted therapy into clinical practice. In this review, we will present the main molecular pathways involved in CRC carcinogenesis, the molecular classifications. The anti-VEGF and anti-EGFR therapies currently used in CRC treatment and those under clinical investigation will also be outlined, as well as the mechanisms of primary and acquired resistance to anti-EGFR monoclonal antibodies (cetuximab and panitumumab). Targeted therapy has led to great improvement in the treatment of metastatic CRC. However, there has been variability in CRC treatment outcomes due to molecular heterogeneity in colorectal tumors, which underscores the need for identifying prognostic and predictive biomarkers for CRC-targeted drugs.
Competing Interests: The authors declare that they have no conflicts of interest.
(Copyright © 2021 Mouade El Bali et al.)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja